Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Huang, Zhe;Wu, Fang;Xu, Qinqin;Song, Lianxi;Zhang, Xiangyu;...

通讯作者：

Yang, N

作者机构：

[Deng, Li; Yang, Nong; Huang, Zhe; Wang, Zhan; Zeng, Liang; Zhang, Xiangyu; Zhang, Yongchang; Song, Lianxi] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp,Hunan Canc Hosp, Dept Med Oncol,Lung Canc & Gastrointestina Unit, Changsha 410013, Hunan, Peoples R China.

[Yang, Nong; Wu, Fang] Cent South Univ, Sch Basic Med, Dept Pathol, Immunooncol Lab, Changsha 410013, Hunan, Peoples R China.

[Xu, Qinqin] Qinghai Prov Peoples Hosp, Dept Med Oncol, Xining 810000, Qinghai, Peoples R China.

[Song, Lianxi; Zhang, Yongchang] Univ South China, Hengyang Med Sch, Dept Med Oncol, Grad Collaborat Training Base Hunan Canc Hosp, Hengyang 421001, Hunan, Peoples R China.

通讯机构：

[Yang, N ] C

Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp,Hunan Canc Hosp, Dept Med Oncol,Lung Canc & Gastrointestina Unit, Changsha 410013, Hunan, Peoples R China.

语种：

英文

关键词：

Brain metastasis;Immune checkpoint inhibitor;Non-small cell lung cancer;Objective response rates;Progression-free survival

期刊：

中华医学杂志(英文版)

ISSN：

0366-6999

年：

2023

卷：

136

期：

页码：

1422-1429

DOI：

10.1097/CM9.0000000000002720

基金类别：

This work received financial support from the National Natural Science Foundation of China (Nos. 82003206 and 82173338) and Natural Science Foundation of Hunan Province (Nos. 2020SK2031, 2020SK2030, 2021RC4040, and 2020JJ3025). The funding agencies had no role in the study design, data collection, analysis, interpretation, manuscript writing, or decision to submit the article for publication.

机构署名：

本校为其他机构

院系归属：

医学院

摘要：

Abstract Background: Immune checkpoint inhibitors (ICIs) are increasingly used as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring no actionable mutations; however, data on their efficacy among patients presenting with intracranial lesions are limited. This study aimed to explore the efficacy and safety of ICIs combined with chemotherapy in advanced NSCLC patients with measurable brain metastasis at initial diagnosis. Methods: Our study retrospectively analyzed clinical data of a total of 211 ...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问